Dekang Healthcare cut sales forecasts for the whole year, the biggest drop in history! Wall Street analysts have mixed reviews
Dekang Medical expects annual revenue of 4 billion-4.05 billion US dollars, and the company originally expected 4.2 billion-4.35 billion US dollars. The adjusted gross profit margin for the full year was expected to be 63%, analysts expected 63.4%, and the company originally expected 63%-64%. Wall Street analysts have mixed reviews.
Express News | Dexcom Outlook FY Revenue USD 4,000-4,050 Million
Heard on the Street Recap: DexCom Bomb -- WSJ
DexCom Options Spot-On: On July 26th, 122.86K Contracts Were Traded, With 123.57K Open Interest
On July 26th ET, $DexCom(DXCM.US)$ had active options trading, with a total trading volume of 122.86K options for the day, of which put options accounted for 38.49% of the total transactions, and
These Stocks Moved the Most Today: DexCom, 3M, Nvidia, Bristol Myers, Coursera, Biogen, Charter, Deckers, and More -- Barrons.com
Are GLP-1 Drugs Creating Headwinds for Medical Device Makers?
Sector Update: Health Care Stocks Higher Late Afternoon
US Equities Markets End Higher Friday as Markets Evaluate Economic Data, Earnings
DexCom Stock Plunges Following Guidance Cut; Results 'Disappointing', Oppenheimer Says
DexCom Is Maintained at Buy by BTIG
S&P 500 Gains Over 1%; 3M Shares Jump After Q2 Results
Equity Markets Rise Intraday After Earnings, Macro Data
DexCom Price Target Cut to $75.00/Share From $120.00 by Morgan Stanley
DexCom's Stock Is Headed for Its Worst Selloff Ever. Not Everyone Thinks It's Justified.
Trending Stocks Today | BurgerFi International Shoots up 130.54%
July 26th - US stocks trending in regular trading hours.Gainers: $BurgerFi International(BFI.US)$ shoots up 130.54% to $0.49 with a turnover of $160.59 million. $Windtree Therapeutics(WINT.US)$
Wall Street Enjoys Late-Week Rally On Benign Inflation Data, Dow Jones Eyes Best Session Of 2024, Tech Unwinding Stalls: What's Driving Markets Friday?
Morgan Stanley Maintains Equal-Weight on DexCom, Lowers Price Target to $75
Dexcom Shares Plunge More Than 40%, Head for Worst Day on Record
Sector Update: Health Care
DexCom Shares Fall After JPMorgan, Baird Downgrades Follow 2024 Revenue Guidance Cut
No Data